Biotech News
Related news
LUNGPulmonx2026-11-18 21:05 EST
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
LUNGPulmonx2026-10-28 20:05 EST
Pulmonx to Participate in Upcoming Investor Conferences
JNJJohnson & Johnson2026-10-25 14:24 EST
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
FEMYFEMASYS2026-10-14 13:00 EST
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
JNJJohnson & Johnson2026-10-24 13:01 EST
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
BSXBoston Scientific2026-11-02 19:02 EST
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
INSMInsmed2026-10-15 11:00 EST
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
IRIXIRIDEX2026-10-12 11:00 EST
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
PAVMPAVmed2026-11-03 13:15 EST
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
ANGOAngioDynamics2026-10-21 12:30 EST
AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
Pulmonx
Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...
Recent company news
LUNGPulmonx2026-11-18 21:05 EST
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
LUNGPulmonx2026-11-17 12:10 EST
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
LUNGPulmonx2026-10-28 20:05 EST
Pulmonx to Participate in Upcoming Investor Conferences
LUNGPulmonx2026-10-27 20:05 EST
Pulmonx Reports Third Quarter 2026 Financial Results
LUNGPulmonx2026-10-13 20:05 EST
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
Stock data
- Close
- 2.74 USD
- Market cap
- 68M USD
- Exchange
- NASDAQ
- Sector
- MedTech
- Location
- United States
